ELDN vs. ORGO, RZLT, TERN, XNCR, TRML, MAZE, SNDL, PVLA, ORKA, and ANAB
Should you be buying Eledon Pharmaceuticals stock or one of its competitors? The main competitors of Eledon Pharmaceuticals include Organogenesis (ORGO), Rezolute (RZLT), Terns Pharmaceuticals (TERN), Xencor (XNCR), Tourmaline Bio (TRML), Maze Therapeutics (MAZE), SNDL (SNDL), Palvella Therapeutics (PVLA), Oruka Therapeutics (ORKA), and AnaptysBio (ANAB). These companies are all part of the "pharmaceutical products" industry.
Eledon Pharmaceuticals vs. Its Competitors
Organogenesis (NASDAQ:ORGO) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.
Organogenesis has a beta of 1.76, suggesting that its stock price is 76% more volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of -0.15, suggesting that its stock price is 115% less volatile than the S&P 500.
In the previous week, Organogenesis and Organogenesis both had 3 articles in the media. Organogenesis' average media sentiment score of 1.20 beat Eledon Pharmaceuticals' score of 0.32 indicating that Organogenesis is being referred to more favorably in the media.
Eledon Pharmaceuticals has a net margin of 0.00% compared to Organogenesis' net margin of -1.92%. Organogenesis' return on equity of -0.37% beat Eledon Pharmaceuticals' return on equity.
49.6% of Organogenesis shares are owned by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 33.0% of Organogenesis shares are owned by insiders. Comparatively, 12.3% of Eledon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Organogenesis has higher revenue and earnings than Eledon Pharmaceuticals. Organogenesis is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Organogenesis currently has a consensus price target of $7.50, indicating a potential upside of 46.48%. Eledon Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 289.11%. Given Eledon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eledon Pharmaceuticals is more favorable than Organogenesis.
Summary
Organogenesis beats Eledon Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Get Eledon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eledon Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ELDN) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access